01—Abstract
Summary
Summary of the 10-Q filed August 2, 2024. Cited figures are marked; the original filing is the authoritative source.
Ecolab Inc. (ECL) reported strong financial results for the second quarter and first six months of 2024, demonstrating significant year-over-year growth in net sales and net income.
Net sales increased by 3% to $3,985.8 milliona in the second quarter and 4% to $7,737.7 million for the first six months, driven by robust organic sales growth across key segments, particularly Global Institutional & Specialty and Global Pest Elimination. The company also saw a substantial increase in operating income, up 36% to $656.9 million for the quarter, reflecting improved gross margins due to lower supply chain costs and effective pricing strategies. The company successfully managed its cost of sales, leading to a notable improvement in gross margin to 43.8% in the second quarter of 2024, up from 39.4% in the prior year.
Net income attributable to Ecolab surged by 49% to $490.9 millionb ($1.71 per diluted share) for the second quarter. This performance was bolstered by strategic initiatives and operational efficiencies, despite some ongoing restructuring costs. Ecolab also completed the sale of its global surgical solutions business on August 1, 2024, which is expected to result in a pre-tax gain.
02—Key points
Key Highlights
- Net sales increased by 3% to $3,985.8 million in Q2 2024 and 4% to $7,737.7 million in H1 2024, driven by strong organic sales growth.
- Operating income rose significantly by 36% to $656.9 million in Q2 2024, indicating improved operational efficiency and profitability.
- Gross margin improved to 43.8% in Q2 2024, up from 39.4% in Q2 2023, attributed to lower supply chain costs and effective pricing.
- Net income attributable to Ecolab grew by 49% to $490.9 million in Q2 2024, with diluted EPS rising to $1.71.
- The company continues to manage its restructuring and integration costs, with the "Combined Program" nearing completion and progress made on the "One Ecolab" initiative.
- Ecolab completed the sale of its global surgical solutions business on August 1, 2024, following its classification as 'held for sale' in Q2 2024.
- Cash flow from operations increased by $488.9 million in H1 2024 compared to H1 2023, demonstrating strong operational cash generation.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q2 FY2024, Ecolab Inc. kept $0.12.
- Revenue$3.99B100.0%
- Cost of revenue−$2.24B56.2%
- Gross profit$1.74B43.8%
- Operating costs−$1.09B27.3%
- Operating income$656.9M16.5%
- Interest, other & tax−$166.0M4.2%
- Net income$490.9M12.3%
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2024filed August 2, 2024Financial Statements
Q2 FY2024 against Q2 FY2023
| Line item | Q2 FY2024Q2 FY2023 | Change |
|---|---|---|
| Revenue | $3.99B$3.85B | +3.5% |
| Cost of Revenue | $2.24B$2.33B | −4.0% |
| Gross Profit | $1.74B$1.52B | +15.0% |
| SG&A Expenses | $1.08B$1.01B | +6.3% |
| Operating Income | $656.90M$484.70M | +35.5% |
| Interest Expense | $80.20M$82.70M | −3.0% |
| Net Income | $490.90M$329.70M | +48.9% |
| EPS (Basic) | $1.72$1.16 | +48.3% |
| EPS (Diluted) | $1.71$1.15 | +48.7% |
| Shares Outstanding (Basic) | 284.60M284.90M | −0.1% |
| Shares Outstanding (Diluted) | 287.00M286.30M | +0.2% |
05—Questions
Frequently Asked Questions
What were the main drivers behind the increase in Ecolab's net sales and profitability?
The increase in net sales and profitability was primarily driven by strong organic sales growth across most segments, particularly Global Institutional & Specialty and Global Pest Elimination. This was complemented by effective pricing strategies and reduced supply chain costs, which led to a significant improvement in gross margins. Operational efficiencies and the successful management of restructuring activities also contributed to the enhanced profitability.
How did the divestiture of the global surgical solutions business impact the financial results?
The global surgical solutions business was classified as 'held for sale' in the second quarter of 2024, with its assets and liabilities presented separately. Ecolab completed the sale of this business on August 1, 2024. While the business's operating results were still included in the financial statements for the second quarter, the sale is expected to contribute a pre-tax gain. The company anticipates this divestiture will streamline its portfolio and focus resources on core growth areas.
What is the outlook for Ecolab's restructuring and cost-saving initiatives?
Ecolab is making progress on its restructuring efforts. The 'Combined Program' related to cost savings in Europe and other regions is nearing completion. Additionally, the company announced the 'One Ecolab' initiative, which includes a new restructuring plan to leverage digital technologies and establish global centers of excellence. This initiative is expected to incur costs of $175 million in restructuring and $50 million in special charges by 2027, with anticipated savings of $140 million by the same year.
How is Ecolab managing its debt and liquidity?
Ecolab maintains a healthy financial position with total debt decreasing to $7.5 billion as of June 30, 2024, from $8.2 billion at the end of 2023. The company has a $2.0 billion revolving credit facility and no outstanding commercial paper as of the reporting date. Cash flow from operations remains strong, providing ample liquidity to fund operations, investments, and shareholder returns, including dividends and share repurchases.
06—Continue